oncoReveal CDx Pan-Cancer Solid Tumor IVD.

Pillar oncoReveal CDx is a US FDA-approved, NGS-based pan-cancer solid tumor test with companion diagnostic claims, offering rapid results in a sample-to-clinical report in less than 48 hours. The kit provides clinically actionable information to consider appropriate companion diagnostic (CDx) therapies in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), and to aid in the identification of other clinically significant genomic alternations for patients with solid tumors. The assay uses proprietary stem loop inhibition-mediated amplification SLIMamp technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.